The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.

Related Articles

The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.

J Med Microbiol. 2019 May 03;:

Authors: Huang DB, Charrier C, Le Bras C, Hawser S, Noviello S

Abstract
The incidence and patient outcomes of Staphylococcus aureus isolates by iclaprim MIC was determined among patients from two phase 3 studies for the treatment of acute bacterial skin and skin structure infections (ABSSSI), REVIVE-1 and -2. Iclaprim MIC90 values were 0.12 µg ml-1 for S. aureus (0.12 µg ml-1 against methicillin-sensitive and 0.25 µg ml-1 against methicillin-resistant S. aureus). The incidence of culture confirmed S. aureus isolates among patients with ABSSSI with an iclaprim MIC > 8 µg ml-1 was 2.0  % (16/790). The clinical outcomes varied by MICs for early clinical response (63-100  %), end of therapy response (81-100  %) and the test of cure response (75-100  %). For microbiological outcomes of these infections, the end of therapy response was 80-100  % and the test of cure response was 88-100  %.

PMID: 31050628 [PubMed - as supplied by publisher]